Bitcoin price today: rises above $111k amid easing trade jitters; US CPI on tap
Investing.com - H.C. Wainwright has reiterated its Buy rating and $12.00 price target on Microbot Medical (NASDAQ:MBOT), representing over 300% upside from the current price of $2.88, following the company’s announcement of a new logistics partnership. According to InvestingPro data, MBOT has shown remarkable strength with a 198% return over the past year, despite a recent 12% pullback last week.
The medical device company revealed Tuesday that it has partnered with a U.S.-based third-party logistics company to support the commercialization of its LIBERTY system, the first FDA-approved, single-use, remotely operated robotic system for peripheral endovascular procedures.
The unnamed logistics partner specializes in the medical device industry and will provide order processing and inventory management from a strategically located, climate-controlled warehouse to meet expected demand for the LIBERTY system.
Microbot Medical remains on track for a limited market release in the U.S. in the fourth quarter of 2025, with a broader launch planned for April 2026 during the Society of Interventional Radiology conference.
The initial addressable market for the LIBERTY system comprises approximately 2.5 million peripheral endovascular procedures annually in the United States, according to H.C. Wainwright’s research note.
In other recent news, Microbot Medical Inc. has announced several significant developments. The company has raised approximately $25.2 million through the exercise of investment options, marking the completion of the first tranche of a two-part offering. This capital raise involved investors purchasing over 12 million shares of common stock. Furthermore, Microbot Medical has secured a partnership with a U.S.-based logistics firm to aid in the commercialization of its FDA-cleared LIBERTY Endovascular Robotic System. The limited market release of this system is planned for the fourth quarter of 2025, with a broader launch anticipated in April 2026.
Additionally, Microbot Medical has issued new equity options and common stock through private placements, with expectations of further exercises of preferred investment options by mid-October 2025. In terms of stock ratings, H.C. Wainwright has reiterated a Buy rating for the company, raising its price target to $12.00 from $9.00, following the FDA’s clearance of the LIBERTY System. The company also received its first patent in Japan for the core technology of the LIBERTY System, which supports its innovative approach in robotic medical devices. These developments highlight Microbot Medical’s strategic efforts to expand its market presence and secure financial growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.